Kantarjian HM - Search Results

1

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Romaguera JE, et al. Among authors: kantarjian hm. Cancer. 2018 Jun 15;124(12):2561-2569. doi: 10.1002/cncr.31361. Epub 2018 May 3. Cancer. 2018. PMID: 29723393 Free article. Clinical Trial.

2

CI-973, a new platinum derivative with potential antileukemic activity.

O'Brien S, Kantarjian H, Freireich E, Johnston D, Nguyen K, Beran M. O'Brien S, et al. Cancer Res. 1992 Aug 1;52(15):4130-4. Cancer Res. 1992. PMID: 1638526

3

Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.

O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M. O'Brien S, et al. Cancer. 1991 Aug 15;68(4):691-4. doi: 10.1002/1097-0142(19910815)68:4<691::aid-cncr2820680404>3.0.co;2-z. Cancer. 1991. PMID: 1855168

4

Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.

Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Schilling PJ, et al. Cancer. 1991 Oct 1;68(7):1536-7. doi: 10.1002/1097-0142(19911001)68:7<1536::aid-cncr2820680713>3.0.co;2-b. Cancer. 1991. PMID: 1893353

5

A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.

Talpaz M, Kurzrock R, Kantarjian H, Rothberg J, Saks S, Evans L, Gutterman JU. Talpaz M, et al. Cancer. 1991 Nov 15;68(10):2125-30. doi: 10.1002/1097-0142(19911115)68:10<2125::aid-cncr2820681006>3.0.co;2-q. Cancer. 1991. PMID: 1913450 Clinical Trial.

6

Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever.

Bodey G, Reuben A, Elting L, Kantarjian H, Keating M, Hagemeister F, Koller C, Velasquez W, Papadopoulos N. Bodey G, et al. Eur J Clin Microbiol Infect Dis. 1991 Jul;10(7):551-8. doi: 10.1007/BF01967272. Eur J Clin Microbiol Infect Dis. 1991. PMID: 1915397 Clinical Trial.

7

Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.

O'Brien S, Witt R, Talpaz M, Kantarjian H. O'Brien S, et al. Cancer. 1991 Apr 1;67(7):1946-9. doi: 10.1002/1097-0142(19910401)67:7<1946::aid-cncr2820670720>3.0.co;2-#. Cancer. 1991. PMID: 2004308

8

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.

Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Grunewald R, et al. Cancer Res. 1990 Nov 1;50(21):6823-6. Cancer Res. 1990. PMID: 2208147

9

Beta-lactam regimens for the febrile neutropenic patient.

Bodey GP, Fainstein V, Elting LS, Anaissie E, Rolston K, Khardori N, Kantarjian H, Plager C, Murphy WK, Holmes F, et al. Bodey GP, et al. Cancer. 1990 Jan 1;65(1):9-16. doi: 10.1002/1097-0142(19900101)65:1<9::aid-cncr2820650105>3.0.co;2-c. Cancer. 1990. PMID: 2403484 Clinical Trial.

10

Rebound peripheral blastosis with subsequent remission during remission induction in a patient with acute promyelocytic leukemia.

Amato R, Kantarjian H, Walters R, Keating M. Amato R, et al. Cancer. 1988 Feb 15;61(4):650-3. doi: 10.1002/1097-0142(19880215)61:4<650::aid-cncr2820610405>3.0.co;2-9. Cancer. 1988. PMID: 3422175

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,003 results

Search Page

Filters